Mounjaro vs. Zepbound
Mounjaro and Zepbound target different primary conditions. Mounjaro is a dual GIP and GLP-1 agonist for type 2 diabetes, while Zepbound, a semaglutide-based GLP-1 agonist, focuses on chronic weight management. Mounjaro delivers superior HbA1c reductions and comparable weight-loss benefits to Zepbound. Neither has significant off-label uses. Side effects like nausea overlap, though Mounjaro’s dual mechanism may elevate thyroid tumor risks. Mounjaro costs $1,135/month, while Zepbound’s cost is unspecified in the data. Neither drug faces shortages.
Enhances the effects of both incretin hormones. GIP improves insulin sensitivity and enhances fat metabolism, while GLP-1 reduces appetite, delays gastric emptying, and promotes insulin secretion, making it effective for blood sugar control and weight loss.
Common Side Effects
Nausea, vomiting, diarrhea, decreased appetite, and indigestion
Serious Potential Side Effects
Pancreatitis, thyroid tumors (potential risk), gallbladder issues, kidney problems, and serious allergic reactions
Enhances the effects of both incretin hormones. GIP improves insulin sensitivity and enhances fat metabolism, while GLP-1 reduces appetite, delays gastric emptying, and promotes insulin secretion, making it effective for blood sugar control and weight loss.
Common Side Effects
Nausea, vomiting, diarrhea, decreased appetite, and indigestion
Serious Potential Side Effects
Pancreatitis, thyroid tumors (potential risk), gallbladder issues, kidney problems, and serious allergic reactions